ClinicalTrials.gg
RecruitingNCT07586397HIPS-RCTUpdated Aug 10, 2026

HIPS Feasibility Randomized Controlled Trial

An interventional study of HIPS-1 and HIPS-2 in Hip Pain Chronic, Hip Pain and Physical Medicine and Rehabilitation, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Chronic Pain by Massachusetts General Hospital — 7 open to participants now, 8 under way, none of them phase 3. Chronic Pain · Massachusetts General Hospital.

Planned enrollment
14th of 23
50 · median 60
Started
2026
with 1 other
No phase
20 of 27
5 open now
Registered
26th of 27
by date

Among the 27 studies in Chronic Pain by Massachusetts General Hospital, this one is the 14th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2026, is one of 20 with no phase, and was the 26th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

7 of the 27 studies in Chronic Pain by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Chronic Pain by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The goal of this clinical trial is to conduct a randomized controlled trial (RCT) to test the feasibility of two dose- and time-matched pain management programs, delivered via live video, for adults with chronic (lasting at least 3 months) and non-arthritic hip-related pain (HRP). Following pre-determined benchmarks, findings from this trial will be used to assess the feasibility, credibility, and acceptability of both programs (HIPS-1, HIPS-2). In preparation for a future clinical trial powered to test efficacy, we will optimize the protocol for patient recruitment, study protocol, and fidelity materials.

Read the detailed description

Aim: Conduct an RCT testing the feasibility of two dose- and time-matched pain management programs, delivered via live video, for adults with chronic (lasting at least 3 months) and non-arthritic HRP. The ultimate goal of this research is to assess the feasibility, credibility, and acceptability of both interventions (HIPS-1, HIPS-2) and optimize the program and study methodology in preparation for a future RCT powered to assess efficacy.

HIPS-1 and HIPS-2 Interventions: Both programs consist of 6 sessions delivered via live video (i.e., Zoom) and are tailored to the needs of patients with non-arthritic HRP seeking physical therapy/rehabilitation. Both programs aim to improve the management of the subjects' HRP by providing helpful information. Sessions, regardless of program assignment, are held weekly. In between sessions, subjects complete a brief check-in survey.

Participants will complete the baseline assessment (i.e., digital self-report survey battery). Following the baseline assessment, participants will be randomized to one of the two conditions (HIPS-1, HIPS-2) and complete their 6 program sessions within approximately 6-weeks. Participants will complete additional survey assessments directly following their final program sessions, and once more, 6 months later.

Assessments: Baseline (0 weeks), post-test (6 weeks), and 6-month follow-up (30 weeks) survey assessments.

03

Conditions studied

  • Hip Pain Chronic
  • Hip Pain
  • Physical Medicine and Rehabilitation

Keywords

  • Intervention feasibility
  • Randomized controlled trial
  • Behavioral intervention development
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Presenting with chronic (lasting ≥3 months) hip joint-related pain
  2. Fluent in English
  3. Age ≥18yr [If ≥45yr, the physician will confirm no osteoarthritis via X-ray (Kellgren Lawrence [KL] grade 0-1)]
  4. Score ≥3 for current hip pain on the Pain-VAS
  5. Psychological risk factor for the maintenance of pain by meeting ≥1 of the criteria listed below:

    1. Score ≥ 20 on the PCS
    2. Score ≤ 40 on the PSEQ
    3. Score ≥ 17 on the TSK-11
  6. Exhibits sedentariness or dissatisfaction with physical activity by meeting ≥1 of the criteria listed below:

    1. Physically active \< 150mins/week according to the IPAQ-SF
    2. Hip pain interferes with the ability to be physically active
    3. Dissatisfaction with the current physical activity level

Exclusion criteria

Exclusion Criteria:

  1. Previous surgery on the symptomatic (painful) hip
  2. Current pain referred from the lower back
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    HIPS-1

    HIPS-1 is a 6-session (one 30-minute session per week) mind-body intervention delivered via live-video (i.e., MGB Zoom) by a trained physical therapist (PT). In addition to participating in the HIPS-1 intervention, all participants will attend their prescribed physical therapy with a PT of their choosing. To minimize variability in physical rehabilitation, we will send the PT the Clinical Practice Guidelines, which outline a standard-of-care rehabilitation protocol. Across these six 30-minute sessions, the HIPS-1 intervention aims to teach relaxation and coping skills and provide pain education. After each session, participants will set a physical activity SMART goal for the coming week and complete a weekly check-in survey (i.e., submit weekly home practice, brief pain assessment). All HIPS-1 sessions will be audio-recorded for subsequent interventionist fidelity checks. These recordings will be stored exclusively on MGB-encrypted devices.

    Behavioral: HIPS-1

  • Active comparator
    HIPS-2

    The HIPS-2 program will be administered via live video (i.e., MGB Zoom) and is time and attention-matched to HIPS-1. As such, HIPS-2 is delivered by a trained PT and consists of 6-sessions (one 30-minute session per week). HIPS-2 contains healthy lifestyle education consistent with public health recommendations, including physical activity, sleep, and nutrition. HIPS-2 has no overlap with HIPS-1. In addition to participating in HIPS-2, all those randomized to this condition will attend their prescribed physical therapy with a PT of their choosing and complete a weekly check-in survey (i.e., brief pain assessment). To minimize variability in physical rehabilitation, we will send the PT the Clinical Practice Guidelines, which outline a standard-of-care rehabilitation protocol. All HIPS-2 sessions will be audio-recorded for subsequent interventionist fidelity checks. These recordings will be stored exclusively on MGB-encrypted devices.

    Behavioral: HIPS-2

Interventions

  • BehavioralHIPS-1

    HIPS-1 is a 6-session (one 30-minute session per week) mind-body intervention delivered via live-video (i.e., MGB Zoom) by a trained physical therapist (PT). In addition to participating in the HIPS-1 intervention, all participants will attend their prescribed physical therapy with a PT of their choosing. To minimize variability in physical rehabilitation, we will send the PT the Clinical Practice Guidelines, which outline a standard-of-care rehabilitation protocol. Across these six 30-minute sessions, the HIPS-1 intervention aims to teach relaxation and coping skills and provide pain education. After each session, participants will set a physical activity SMART goal for the coming week and complete a weekly check-in survey (i.e., submit weekly home practice, brief pain assessment). All HIPS-1 sessions will be audio-recorded for subsequent interventionist fidelity checks. These recordings will be stored exclusively on MGB-encrypted devices.

  • BehavioralHIPS-2

    The HIPS-2 program will be administered via live video (i.e., MGB Zoom) and is time and attention-matched to HIPS-1. As such, HIPS-2 is delivered by a trained PT and consists of 6-sessions (one 30-minute session per week). HIPS-2 contains healthy lifestyle education consistent with public health recommendations, including physical activity, sleep, and nutrition. HIPS-2 has no overlap with HIPS-1. In addition to participating in HIPS-2, all those randomized to this condition will attend their prescribed physical therapy with a PT of their choosing and complete a weekly check-in survey (i.e., brief pain assessment). To minimize variability in physical rehabilitation, we will send the PT the Clinical Practice Guidelines, which outline a standard-of-care rehabilitation protocol. All HIPS-2 sessions will be audio-recorded for subsequent interventionist fidelity checks. These recordings will be stored exclusively on MGB-encrypted devices.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Who Scored Above the Midpoint on the Client Satisfaction Scale (CSQ)

    Measured using the CSQ, which assesses participants' satisfaction with participation in the study. The score range is 0-12, with higher scores indicating greater satisfaction.

    Time frame: Post-Test (6 Weeks)

  2. Proportion of Participants Who Scored Above the Midpoint on Each Subscale of the Credibility and Expectancy Questionnaire (CEQ)

    Assessed using the CEQ, which asks the participant to indicate how much they believe, right now, that the intervention they will receive will help manage their HRP and related worry. Possible scores range from 3 to 27 for both the credibility and the expectancy subscales. Higher scores represent higher credibility and expectancy.

    Time frame: Baseline (0 Weeks)

  3. Feasibility of recruitment

    The percent of eligible patients approached that agree to participate.

    Time frame: Baseline (0 Weeks)

  4. Rate at which program was accepted, measured by number of completed program sessions

    The proportion of participants who attend ≥4 of 6 sessions.

    Time frame: Post-Test (6 Weeks)

  5. Feasibility of Assessments at Baseline

    Rate of participant's completion of self-report measures, with no measures missing.

    Time frame: Baseline (0 Weeks)

  6. Feasibility of Assessments at Post-Test

    Rate of participant's completion of self-report measures, with no measures missing.

    Time frame: Post-Test (6 Weeks)

  7. Feasibility of Assessments at Follow-Up

    Rate of participant's completion of self-report measures, with no measures missing.

    Time frame: Follow-Up (30 Weeks)

  8. Intervention fidelity

    Rate of interventionists delivering the programs by following the established session topics and practices.

    Time frame: Collected during intervention, an average of 6 weeks

  9. Proportion of participants who report symptom improvements as measured by the Global Rating of Change (GRoC) Scale

    The proportion of participants who report overall improvement on the GRoC Scale. This measure includes a single question asking the patient to rate their change with respect to their hip condition over the last 6 weeks. Higher scores indicate better outcomes.

    Time frame: Post-Test (6 Weeks)

  10. Adverse Events

    Any self-reported or observed negative events related to participation.

    Time frame: Collected during intervention, an average of 6 weeks

Secondary outcomes

  1. Pain Visual Analogue Scale (Pain-VAS)

    The Pain-VAS is a single-item scale measuring self-reported pain intensity (worst and average). Scores on the Pain-VAS range from 0 (no pain) to 100 (worst pain imaginable), and higher scores equate to worse outcomes.

    Time frame: Baseline (0 Weeks), Post-Test (6 Weeks), Follow-Up (30 Weeks)

  2. International Hip Outcome Tool (iHOT-12)

    The iHOT-12 is a 12-item questionnaire to assess deficiencies with respect to outcome assessment for young, active patients with hip disorders. Total scores range from 0 to 100, and higher scores represent better outcomes.

    Time frame: Baseline (0 Weeks), Post-Test (6 Weeks), Follow-Up (30 Weeks)

  3. PROMIS Pain Interference - Short Form 6b

    This is a 6-item measure assessing self-reported consequences of pain on relevant aspects of a person's life and including the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. Scores range from 6 to 30, where higher scores indicate worse outcomes.

    Time frame: Baseline (0 Weeks), Post-Test (6 Weeks), Follow-Up (30 Weeks)

  4. Brief Multidimensional Assessment of Interoceptive Awareness 2.0 (MAIA)

    The MAIA-2.0 is a 24-item state-trait questionnaire to measure multiple dimensions of interoception. Each item is scored on a 0 to 5 scale. Higher scores translate to better outcomes.

    Time frame: Baseline (0 Weeks), Post-Test (6 Weeks), Follow-Up (30 Weeks)

  5. Pain Catastrophizing Scale (PCS)

    The PCS is a 13-item questionnaire assessing one's tendency to focus on pain-related thoughts and feel helpless and hopeless due to pain on a scale of 0 to 4. Total scores range from 0 to 25, and higher scores indicate higher pain catastrophizing (worse outcomes).

    Time frame: Baseline (0 Weeks), Post-Test (6 Weeks), Follow-Up (30 Weeks)

  6. International Physical Activity Questionnaire - Short Form (IPAQ-SF)

    The IPAQ-SF is a 7-item self-reported measure assessing physical activity. Overall scores on this measure are calculated using responses to all questions. More physical activity translates to better outcomes.

    Time frame: Baseline (0 Weeks), Post-Test (6 Weeks), Follow-Up (30 Weeks)

  7. Tampa Kinesiophobia Scale (TSK-11)

    The TSK-11 is an 11-item questionnaire assessing fear avoidance and fear of activity. Summary scores range from 11 (minimum) to 44 (maximum). Higher scores indicate higher kinesiophobia and worse outcomes.

    Time frame: Baseline (0 Weeks), Post-Test (6 Weeks), Follow-Up (30 Weeks)

  8. Pain Self-Efficacy Questionnaire (PSEQ)

    The PSEQ is a 10-item measure assessing the confidence those with ongoing pain have in performing activities while in pain. Each item is scored on a 7-point Likert scale, where 0 = "not at all confident" and 6 = "completely confident". Total scores range from 0 to 60, and higher scores translate to better outcomes.

    Time frame: Baseline (0 Weeks), Post-Test (6 Weeks), Follow-Up (30 Weeks)

  9. Defense and Veterans Pain Rating Scale (DVPRS) - Pain Interference

    The DVPRS for Pain Interference is a 5-item measure assessing pain interference on a 10-point Likert scale where 10 = "complete interference" and 0 = "no interference". Higher scores indicate worse outcomes.

    Time frame: Baseline (0 Weeks), Post-Test (6 Weeks), Follow-Up (30 Weeks)

  10. Chronic Pain Acceptance Questionnaire (CPAQ-8)

    The CPAQ-8 is an 8-item measure assessing acceptance of pain on two sub-scales (Activity Engagement and Pain Willingness). Higher scores indicate higher levels of acceptance and better outcomes.

    Time frame: Baseline (0 Weeks), Post-Test (6 Weeks), Follow-Up (30 Weeks)

  11. Pain Resilience Scale (PRS)

    The PRS is a 14-item measure assessing pain resilience on two main dimensions (cognitive/affective positivity and behavioral perseverance). Respondents rate each item on a 0 ("Not at all") to 4 ("All the time") scale. Higher total scores indicate better outcomes (greater resilience).

    Time frame: Baseline (0 Weeks), Post-Test (6 Weeks), Follow-Up (30 Weeks)

  12. World Health Organization - Five Well-Being Index (WHO-5)

    The WHO-5 Well-Being Index is a 5-item measure assessing general mental well-being on a 6-point scale. Raw score ranges from 0 to 25. To calculate the final score, the raw score is multiplied by 4, producing a percentage score from 0 to 100, where greater scores reflect better well-being.

    Time frame: Baseline (0 Weeks), Post-Test (6 Weeks), Follow-Up (30 Weeks)

  13. Brief Pain Catastrophizing Scale (PCS-3)

    The PCS-3 is a 3-item version of the PCS assessing one's tendency to focus on pain-related thoughts and feel helpless and hopeless due to pain on a 0 to 4 scale. Total scores range from 0 to 12, and higher scores indicate higher pain catastrophizing (worse outcomes).

    Time frame: Collected weekly thoughout intervention, an average of 6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No identifiable IDP will be shared with any other researchers. De-identified data may be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 16 months is below that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
May 14, 2026
StartActual
Jul 20, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Jun 1, 2028
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07586397
Responsible party
Kate Jochimsen (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
May 14, 2026
Start date
Jul 20, 2026
Primary completion
Dec 1, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Aug 10, 2026

Study contacts

Kate Jochimsen, PhD, ATC
Contact
kjochimsen@mgh.harvard.edu
920-948-7812
Kate Jochimsen, PhD, ATC
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion